Hormones
Testosterone
Topical
Hormone health
CJC-1295 / Ipamorelin
Understand this experimental peptide combination and its evidence limitations.
Medical guidance
Clinical review required
This listing is educational only. It is not offered for ordering, and no supply can be reserved here.
Availability and treatment are not guaranteed.
vidameds
Compounded medications are not FDA-approved.
Understanding CJC-1295 / Ipamorelin
Know the treatment.
Ask better questions.
CJC-1295 / Ipamorelin is the peptide combination pictured here. These experimental peptides affect growth-hormone signaling; this combination is not an FDA-approved treatment.
How it works
CJC-1295 is studied as a growth-hormone-releasing hormone analog, while ipamorelin acts on growth-hormone secretagogue pathways. Those mechanisms do not establish benefits for healthy aging, recovery, or performance.
Safety & suitability
The exact formulation and whether CJC-1295 includes a drug affinity complex must be confirmed. Human safety, dosing, interactions, and long-term effects of the combination are not established. Endocrine conditions and other medical history require careful review.
Bring to your care conversation
- What evidence exists for this exact combination rather than one ingredient?
- What is the exact formulation, and which approved alternatives should I consider?
- What side effects, interactions, and follow-up should we discuss before a decision?
Research, in perspective
What the evidence says.
Hormone signals are not the same as health outcomes.
Short studies of long-acting CJC-1295 alone in healthy adults measured increases in growth hormone and IGF-1. They did not demonstrate improved recovery, strength, fat loss, or lifespan.
Those studies do not validate a CJC-1295 / ipamorelin blend or a formulation without a drug affinity complex. FDA identifies safety and impurity concerns for these compounding substances.
Read the sourcesEvidence at a glance
What has been studied
Short-term biomarkers for long-acting CJC-1295 alone.
What remains unknown
Patient-important outcomes and long-term safety of the combination.
What this means for you
Evidence must match the ingredient, formulation, and condition. A biological mechanism is not a guaranteed clinical result.
01
Two growth-hormone-related signaling pathways
02
Changes in hormone biomarkers
03
Combination-specific benefit and safety remain unestablished
Sources & further reading
- 01CJC-1295: Growth hormone and IGF-1 in healthy adults (2006)
- 02FDA: Compounding substances with potential significant safety risks
Research context is educational and does not confirm the safety, effectiveness, or availability of the pictured product.
The Vida Meds difference
Connected care.
Personal at every step.
A nationwide provider network. Direct pharmacy pricing. A team you can reach.
200+
Licensed providers
A nationwide network of licensed clinicians.
50 states
Nationwide care
Our provider network spans all 50 states.
Direct pharmacy
Pricing
Direct Pharmacy Pricing for your treatment.
Overnight
ColdChain Shipping
Temperature-controlled shipping for medications that require it.
24-hour
Customer support
Support for your questions, around the clock.
Direct access
Patient portal
Connect with your provider and dedicated care team.
Treatment eligibility, medication availability, and shipping arrangements depend on clinical review and the prescribed medication. Customer support is not emergency care; call 911 for a medical emergency.
Beyond the medication
Find your balance. On your terms.
Changes in energy, mood, and wellbeing deserve a thoughtful conversation. Explore hormone care informed by symptoms, appropriate testing, and your individual needs.
Explore hormone health
